Nanobiotix Secures Cash Runway into 2029 with €86.1M Offering Completion
Summary
Nanobiotix announced the completion of its €86.1 million follow-on offering, extending its cash runway into 2029 and providing financial stability for its clinical development programs.
Key Events
-
Offering Completion
Successfully completed a follow-on offering in May 2026, raising approximately €86.1 million in gross proceeds.
-
Extended Cash Runway
The company now has sufficient cash and cash equivalents to fund operations into 2029, significantly de-risking its operations.
-
Clinical Data Update
Reiterated promising Part 1 data from the Phase 2 CONVERGE study in NSCLC, showing an 85.7% overall response rate and 57.1% complete response rate.
-
Regulatory Progress
FDA accepted a protocol amendment for the pivotal Phase 3 NANORAY-312 study, eliminating an interim analysis and modifying the final analysis for an earlier readout.
Analysis
This filing confirms the successful completion of Nanobiotix's follow-on offering, raising approximately €86.1 million. Crucially, this capital raise, combined with existing cash, extends the company's operational cash runway into 2029. For a late-clinical stage biotechnology company, securing long-term funding significantly de-risks its development programs and provides stability to advance its pipeline, including the JNJ-1900 (NBTXR3) and Nanoprimer platforms. The update also reiterates positive clinical data and regulatory progress, reinforcing the company's operational momentum.
At the time of this filing, NBTX was trading at $36.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $4.06 to $57.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.